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The antifungal susceptibility profiles of the mycelial and yeast forms of 23Histoplasma capsulatum strains from pulmonary and
disseminated histoplasmosis patients in India are reported here. TheMIC data of this dimorphic fungus had good agreement
between both forms for azoles, amphotericin B, and caspofungin. Therefore, the use of mycelial inocula forH. capsulatum anti-
fungal susceptibility testing is suggested, which is less time-consuming vis-à-vis the yeast form, which requires 6 to 8 weeks for
conversion.
Histoplasma capsulatum is the causative agent of histoplasmo-sis, a disease that is endemic in the Americas, Asia, andAfrica,
with sporadic cases reported worldwide (1). The clinical manifes-
tations range from acute pulmonary to disseminated histoplas-
mosis, with histoplasmosis developing in immunocompromised
patients (2). Therapy with amphotericin B and itraconazole is
commonly used for the disseminated andmild tomoderate forms
of histoplasmosis, respectively (3). However, treatment with itra-
conazole and amphotericin B is limited by variable absorption/
metabolism and toxicity, respectively. Treatment is often noncu-
rative, and relapse and recrudescence can occur even while
patients are on therapy (4). Furthermore, in vitro antifungal sus-
ceptibility testing of this dimorphic fungus remains unstandard-
ized. In addition, no consensus exists regarding testing of the
pathogenic yeast form, which occurs in tissues, or the sapro-
trophic mold form present in the environment, which causes in-
fection by inhaling microconidia. Differences in the antifungal
susceptibilities of the two forms of this dimorphic pathogen were
suggested in a solitary report of 4 isolates ofH. capsulatum, reveal-
ing lowMICs for fluconazole and high MICs for micafungin with
the yeast form vis-à-vis the mycelial form (5). We report here the
in vitro antifungal susceptibility profiles against 8 antifungals of
both the mycelial and yeast forms of 23 molecularly characterized
H. capsulatum strains from patients in India with pulmonary and
disseminated histoplasmosis. Further, we correlated the MICs of
H. capsulatum with clinical outcome.
Twenty-oneH. capsulatum var. capsulatum isolates originating
from 19 (1.9%) patients were cultured from 1,261 clinical speci-
mens of 952 patients with pulmonary or systemic infection from
tertiary care hospitals in northwestern India during 2010 to 2013.
The clinical specimens comprised blood, bone marrow, bron-
choalveolar lavage fluid, lung and skin biopsy specimens, lymph
node aspirates, and sputum. The isolates, along with 2 reference
strains (H. capsulatumCDC B-5324 and ATCC 66368), were sub-
jected to yeast conversion at 37°C on brain heart infusion (BHI)
slants containing glutamine. The isolates were serially transferred
onto fresh BHI slants every 5 to 6 days, and after 8 to 10 transfers,
they revealed small (2 to 5 m in diameter) yeast-like cells with
narrow-based budding in 6 to 8 weeks. Sequencing of the D1/D2
large subunit (LSU) region of the isolates was done using theNL-1
and NL-4 primers, as described previously (26). GenBank
searches of the sequences showed 99% identity with Ajellomyces
capsulatus (GenBank accession no. HM595605.1).
Antifungal susceptibility testing (AFST) of both forms was de-
termined by broth microdilution using CLSI documents M27-A3
and M38-A2 (6, 7). The 8 to 10 days of hyphal growth on Sab-
ouraud’s dextrose agar (SDA) at 28°C was used for preparing the
inoculum for the mycelial form, which was adjusted to an optical
density at 530 nm of 0.20 to 0.24, diluted 1:10 in RPMI 1640
medium to obtain 2.5 105 to 5 105 conidia/hyphal fragments
perml. The plateswere incubated at 28°C for 96 to 120 h. The yeast
inocula, prepared from growth on BHI agar, were adjusted to 5
McFarland standard, diluted 1:100 in RPMI 1640 to obtain 1 
105 to 2.5 105CFU/ml, and the plates were incubated at 37°C for
72 to 96 h (8). The antifungals testedwere amphotericin B (Sigma,
St. Louis, MO, USA), fluconazole (Pfizer, Groton, CT, USA), itra-
conazole (Lee Pharma, Hyderabad, India), voriconazole (Pfizer),
posaconazole (Merck, Whitehouse Station, NJ, USA), isavucona-
zole (Astellas, USA), 5-flucytosine (Sigma), and caspofungin
(Merck). The final concentrations of the drugs ranged from 0.125
to 64g/ml for fluconazole and 5-flucytosine, 0.03 to 16g/ml for
amphotericin B, itraconazole, and voriconazole, and 0.015 to 8
g/ml for posaconazole, isavuconazole, and caspofungin. The
CLSI-recommended reference strainsAspergillus fumigatusATCC
204305 and Paecilomyces variotii ATCC 3630, were included with
each test of the mycelial form, and Candida krusei strain ATCC
6258 and Candida parapsilosis strain ATCC 22019 were used for
testing the yeast form. The MIC endpoints were read visually and
for azoles and 5-flucytosine were defined as the lowest concentra-
tion yielding 80% inhibition of growth for the yeast form and 50%
inhibition of growth for the mycelial form compared with the
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growth of the drug-free control wells. For amphotericin B, 100%
inhibition of growth was considered for both forms. For caspo-
fungin, the minimal effective concentration (MEC) against the
mycelial formwas defined as the lowest concentration of drug that
led to the growth of small, rounded, and compact hyphal forms,
whereas theMIC of the yeast form was defined as 50% inhibition.
The geometric mean of MICs/MECs (GM) and MICs/MECs at
which 50% (MIC50/MEC50) and 90% (MIC90/MEC90) of the
tested isolateswere inhibited for each drugwere determined (8, 9).
Furthermore, viability testing of the mycelial growth was done by
streaking 20 l of each suspension from the well, which showed
complete inhibition, as well as the preceding two lower dilutions
on SDA plates, and incubation at 28°C. The MICs/MECs of the
quality control strains were in the CLSI-recommended ranges,
and for all isolates, the drugs tested revealed reproducible MICs/
MECs when performed by different personnel on two occasions,
revealing only 1-fold difference in the dilutions. All procedures
involving sporulating cultures of H. capsulatum were performed
inside a class II biological safety cabinet under conditions of bio-
safety level 3 (BSL3) containment (10).
The results of AFST and the essential agreement between the
two forms ofH. capsulatum are presented in Table 1. Themycelial
and the yeast forms of the isolates were inhibited by itraconazole,
posaconazole, voriconazole, amphotericin B, and the new drug
isavuconazole. Previously, a solitary study reported isavuconazole
MICs of themold form of 28H. capsulatum isolates (9). Addition-
ally, 13% of the yeast forms revealed high caspofungin MICs of
0.5 g/ml, which is in consonance with Kohler et al. (11), who
demonstrated that caspofungin is not effective against this fungus.
All the isolates in this study had high MICs for fluconazole and
5-flucytosine. Although the established treatment options for H.
capsulatum include azoles, amphotericin B, and echinocandins,
no comparative trials of these agents have been performed. Flu-
conazole treatment failure has been reported in cases of histoplas-
mosis, being partially attributed to isolates that demonstrated
drug MICs of5 g/ml (8). However, in a mouse model, diver-
gent observations suggesting fluconazole to be more efficacious
against histoplasmosis caused by a fluconazole-resistant strain
than by a fluconazole-susceptible strain have been reported (12).
Further, there are studies reporting disagreements between in
vitro and in vivo activities against H. capsulatum for caspofungin
using either the yeast or mold form (11, 13). Notwithstanding the
fact that the host immune status plays a vital role in patient recov-
ery, susceptibility testing of dimorphic fungi yields basic informa-
tion pertaining to its resistance and estimation of clinical value of
the therapeutic agent. Therefore, emphasis on a standardized
method for in vitro susceptibility testing and in vivo studies corre-
lating both growth forms with the therapeutic outcome in dimor-
phic fungi is needed.
Of the 19 histoplasmosis cases, the therapy and outcome re-
cords of 18 patients were available, which included 12 dissemi-
nated, 4 chronic, and 2 acute pulmonary histoplasmosis cases.
Out of the 12 disseminated cases, 6 patients died due to a misdi-
agnosis of tuberculosis with multiple courses of antituberculosis
therapy. Of the remaining 6 disseminated cases, 2 patients died
after treatment with amphotericin B deoxycholate (AMB) (1
mg/kg of body weight) for 1 to 2 weeks. The remaining 4 were
treated with AMB for 2 weeks, followed by 200 mg itraconazole
twice daily for 6 to 12 months. The 6 pulmonary histoplasmosis
cases were treated with 200 mg itraconazole twice daily for 3
months and 12 months for acute and chronic cases, respectively.
These patients had no recrudescence after 12 to 18 months of
follow-up.
The AFST data for H. capsulatum so far have been reported
predominantly from the United States and Mexico, and a single
report is from Brazil (Table 2) (8, 9, 11, 12, 14–22). Although the
disease is endemic in Asia, including India, there are a paucity of
data on AFST and the treatment outcome of the pathogen from
this part of the world. Unlike in North and South America, dis-
seminated disease in India is predominantly seen in HIV-negative
patients who are often misdiagnosed as having tuberculosis and,
consequently, are not correctly treated (23, 24). In the present
study, all disseminated cases wereHIVnegative. Notably, working
with the mycelial morphotype, which is the infective form, re-
quires BSL3 containment conditions, which are cumbersome
(10). AFST studies for testing the mycelial form are limited, and
no comparison has been made in the susceptibility differences
with the parasitic yeast form (5, 11, 12, 14, 20, 21). The mycelial
phase transforms to the yeast phase within 48 h of infection, sug-
gesting that outcome relates more to the antifungal activity to the
yeast phase than to the mycelial form (5). However, the mycelial
form of a dimorphic fungus can coexist with yeast cells in vivo and
TABLE 1 In vitro antifungal susceptibility profile of mycelial and yeast forms of 23 clinical strains of H. capsulatum against 8 antifungal drugs
H. capsulatum form Parameter(g/ml)
Data for antibiotica:
AMB ITC VRC POS ISA CASb FLU 5-FC
Mycelial GM 0.11 0.043 0.102 0.05 0.055 0.097 7.05 64
MIC50/MEC50 0.125 0.03 0.125 0.06 0.06 0.125 8 32
MIC90/MEC90 0.25 0.125 0.25 0.125 0.25 0.25 16 64
Range 0.03 to 0.25 0.03 to 0.125 0.03 to 0.25 0.015 to 0.125 0.015 to 0.25 0.015 to 0.5 2 to 32 8 to64
Yeast GM 0.13 0.051 0.17 0.085 0.04 0.17 4.56 48.2
MIC50 0.125 0.06 0.25 0.06 0.06 0.25 4 16
MIC90 0.25 0.125 0.5 0.25 0.125 0.5 8 64
Range 0.03 to 0.5 0.03 to 0.25 0.03 to 0.5 0.03 to 0.5 0.015 to 0.125 0.03 to 1 2 to 8 8 to 64
Essential agreement (%)c 100 100 100 87 100 96 100 100
a AMB, amphotericin B; ITC, itraconazole; VRC, voriconazole; POS, posaconazole; ISA, isavuconazole; CAS, caspofungin; FLU, fluconazole; 5-FC, flucytosine.
b For caspofungin, the minimal effective concentration (MEC) was read for testing the mycelial form.
c MIC discrepancies of more than two dilutions were used to calculate the essential agreement.
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might be more virulent and invasive, leading to dissemination
(25).
The present comprehensive study reports the MIC data of a
large number of isolates and revealed good essential agreement
with the MICs of both the forms, which were 87 to 100% for
azoles, 100% for amphotericin B, and 96% for caspofungin. The
use of mycelial inocula for H. capsulatum AFST testing in future
studies is suggested, considering that testing of the mycelial form
is less time-consuming (12 to 15 days) vis-à-vis that for the yeast
form (6 to 8 weeks), which requires cumbersome conversion and
is prone to contamination.
Nucleotide sequence accession numbers. The LSU sequences
of 21H. capsulatum isolates are deposited in GenBank with acces-
sion no. KJ653230 to KJ653245 and KJ939255 to KJ939260.
ACKNOWLEDGMENTS
This work was carried out, in part, with financial assistance from the
Indian Council ofMedical Research (ref. 5/3/3/26/2010-ECD-I), Govern-
ment of India, New Delhi, India.
J.F.M. received grants from Astellas andMerck. He has been a consul-
tant to Basilea andMerck and has received speaker’s fees fromMerck and
Gilead. All other authors declare no potential conflicts of interest. The
authors alone are responsible for the content and writing of the paper.
REFERENCES
1. Wheat LJ. 2006. Histoplasmosis: a review for clinicians from non-
endemic areas. Mycoses 49:274–282. http://dx.doi.org/10.1111/j.1439
-0507.2006.01253.x.
2. Kauffman CA. 2007. Histoplasmosis: a clinical and laboratory update.
Clin. Microbiol. Rev. 20:115–132. http://dx.doi.org/10.1128/CMR.00027
-06.
3. Wheat J, Sarosi G, McKinsey D, Hamill R, Bradsher R, Johnson P, Loyd
J, Kauffman C. 2000. Practice guidelines for the management of patients
with histoplasmosis. Clin. Infect. Dis. 30:688–695. http://dx.doi.org/10
.1086/313752.
4. Hecht FM, Wheat J, Korzun AH, Hafner R, Skahan KJ, Larsen R,
Limjoco MT, Simpson M, Schneider D, Keefer MC, Clark R, Lai KK,
Jacobson JM, Squires K, Bartlett JA, Powderly W. 1997. Itraconazole
maintenance treatment for histoplasmosis in AIDS: a prospective, multi-
center trial. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 16:100–
107. http://dx.doi.org/10.1097/00042560-199710010-00005.
5. Nakai T, Uno J, Ikeda F, Tawara S, Nishimura K, Miyaji M. 2003. In
vitro antifungal activity of micafungin (FK463) against dimorphic fungi:
comparison of yeast-like and mycelial forms. Antimicrob. Agents Che-
mother. 47:1376–1381. http://dx.doi.org/10.1128/AAC.47.4.1376-1381
.2003.
6. Clinical and Laboratory Standards Institute. 2008. Reference method for
broth dilution antifungal susceptibility testing of yeasts; approved stan-
dard—3rd ed. CLSIM27-A3. Clinical and Laboratory Standards Institute,
Wayne, PA.
7. Clinical and Laboratory Standards Institute. 2008. Reference method for
broth dilution antifungal susceptibility testing of filamentous fungi; ap-
proved standard—2nd ed. CLSI M38-A2. Clinical and Laboratory Stan-
dards Institute, Wayne, PA.
8. Wheat LJ, Connolly P, Smedema M, Brizendine E, Hafner R, AIDS
Clinical Trials Group and the Mycoses Study Group of the National
Institute of Allergy and Infectious Diseases. 2001. Emergence of resis-
tance to fluconazole as a cause of failure during treatment of histoplasmo-
sis in patients with acquired immunodeficiency disease syndrome. Clin.
Infect. Dis. 33:1910–1913. http://dx.doi.org/10.1086/323781.
9. González GM. 2009. In vitro activities of isavuconazole against opportu-
nistic filamentous and dimorphic fungi. Med. Mycol. 47:71–76. http://dx
.doi.org/10.1080/13693780802562969.
10. Wilson DE, Chosewood CL. 2007. Biosafety in microbiological biomed-
ical laboratories, 5th ed. U.S. Government Printing Office, Washington,
DC.
11. Kohler S, Wheat LJ, Connolly P, Schnizlein-Bick C, Durkin M, Smedema
M, Goldberg J, Brizendine E. 2000. Comparison of the echinocandin caspo-
funginwithamphotericinB for treatmentofhistoplasmosis followingpulmo-
nary challenge in amurinemodel. Antimicrob.AgentsChemother. 44:1850–
1854. http://dx.doi.org/10.1128/AAC.44.7.1850-1854.2000.
12. Kobayashi GS, Travis SJ, Rinaldi MG, Medoff G. 1990. In vitro and in
vivo activities of Sch 39304, fluconazole, and amphotericin B againstHis-
toplasma capsulatum. Antimicrob. Agents Chemother. 34:524–528. http:
//dx.doi.org/10.1128/AAC.34.4.524.
13. Graybill JR, Najvar LK, Montalbo EM, Barchiesi FJ, Luther MF, Rinaldi
MG. 1998. Treatment of histoplasmosis with MK-0991 (L-743,872). An-
timicrob. Agents Chemother. 42:151–153.
14. Wheat J, Marichal P, Vanden Bossche H, Le Monte A, Connolly P.
1997. Hypothesis on the mechanism of resistance to fluconazole inHisto-
plasma capsulatum. Antimicrob. Agents Chemother. 41:410–414.
15. Espinel-Ingroff A. 1998. In vitro activity of the new triazole voriconazole
(UK-109,496) against opportunistic filamentous anddimorphic fungi and
common and emerging yeast pathogens. J. Clin. Microbiol. 36:198–202.
16. Espinel-Ingroff A. 1998. Comparison of in vitro activities of the new
triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and
LY303366 against opportunistic filamentous and dimorphic fungi and
yeasts. J. Clin. Microbiol. 36:2950–2956.
17. Li RK, Ciblak MA, Nordoff N, Pasarell L, Warnock DW, McGinnis MR.
2000. In vitro activities of voriconazole, itraconazole, and amphotericin B
against Blastomyces dermatitidis, Coccidioides immitis, and Histoplasma
capsulatum. Antimicrob. Agents Chemother. 44:1734–1736. http://dx.doi
.org/10.1128/AAC.44.6.1734-1736.2000.
18. Espinel-Ingroff. 2003. In vitro antifungal activities of anidulafungin and
micafungin, licensed agents and the investigational triazole posaconazole
as determined byNCCLSmethods for 12,052 fungal isolates: review of the
literature. Rev. Iberoam Micol. 20:121–136.
19. González GM, Fothergill AW, Sutton DA, Rinaldi MG, Loebenberg D.
2005. In vitro activities of new and established triazoles against opportu-
nistic filamentous and dimorphic fungi. Med. Mycol. 43:281–284. http:
//dx.doi.org/10.1080/13693780500088416.
20. Wheat LJ, Connolly P, Smedema M, Durkin M, Brizendine E, Mann P,
Patel R, McNicholas PM, Goldman M. 2006. Activity of newer triazoles
against Histoplasma capsulatum from patients with AIDS who failed flu-
conazole. J. Antimicrob. Chemother. 57:1235–1239. http://dx.doi.org/10
.1093/jac/dkl133.
21. Brilhante RS, Fechine MA, Mesquita JR, Cordeiro RA, Rocha MF,
Monteiro AJ, Lima RA, Caetano ÉP, Pereira JF, Castelo-Branco DS,
Camargo ZP, Sidrim JJ. 2012. Histoplasmosis in HIV-positive patients in
Ceará, Brazil: clinical-laboratory aspects and in vitro antifungal suscepti-
bility of Histoplasma capsulatum isolates. Trans. R. Soc. Trop. Med. Hyg.
106:484–488. http://dx.doi.org/10.1016/j.trstmh.2012.05.003.
22. Yamazaki T, Inagaki Y, Fujii T, Ohwada J, Tsukazaki M, Umeda I,
Kobayashi K, Shimma N, Page MG, Arisawa M. 2010. In vitro activity of
isavuconazole against 140 reference fungal strains and 165 clinically iso-
lated yeasts from Japan. Int. J. Antimicrob. Agents 36:324–331. http://dx
.doi.org/10.1016/j.ijantimicag.2010.06.003.
23. Johnson PC, Sarosi GA. 1994. Progressive disseminated histoplasmosis
in patients with AIDS. HIV Adv. Res. Ther. 4:15–21.
24. Kathuria S, Capoor MR, Yadav S, Singh A, Ramesh V. 2013. Dissemi-
nated histoplasmosis in an apparently immunocompetent individual
fromnorth India: a case report and review.Med.Mycol. 51:774–778. http:
//dx.doi.org/10.3109/13693786.2013.777166.
25. Schumacher LL, Love BC, Ferrell M, DeSilva U, Fernando R, Ritchey JW.
2013.Canine intestinalhistoplasmosis containinghyphal forms. J.Vet.Diagn.
Invest. 25:304–307. http://dx.doi.org/10.1177/1040638713479604.
26. Kurtzman CP, Robnett CJ. 1997. Identification of clinically important
ascomycetous yeasts based on nucleotide divergence in the 5= end of the
large-subunit (26S) ribosomal DNA gene. J. Clin. Microbiol. 35:1216–
1223.
Kathuria et al.
5616 aac.asm.org Antimicrobial Agents and Chemotherapy
 o
n
 M
ay 1, 2017 by UNIVERSITEITSBIBLIO
THEEK
http://aac.asm
.org/
D
ow
nloaded from
 
